The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2019 | Result of venetoclax plus/minus azacitidine for R/R MDS
Amer Zeidan, MBBS, MHS, Yale University and Yale Cancer Center, New Haven, CT, discusses the updated data from the ongoing phase 1b, open-label, multicenter study (NCT02966782) evaluating the safety and pharmacokinetics of venetoclax as a single-agent and in combination with azacitidine in relapsed/refractory myelodysplastic syndromes (MDS). This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
